Evidence map›Paper›PMID 31409882›Full record

ArticleScientific reports2019

A next generation setup for pre-fractionation of non-denatured proteins reveals diverse albumin proteoforms each carrying several post-translational modifications.

Heidrun Rhode, Petra Muckova, Rita Büchler, Sindy Wendler, Bärbel Tautkus, Michaela Vogel, Thomas Moore, Julian Grosskreutz, Andree Klemm, Mary Nabity

Abstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Transmembrane protease serine 5: a novel Schwann cell plasma marker for CMT1A.Annals of clinical and translational neurology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Heidrun RhodeInstitute of Biochemistry I, Nonnenplan 2-4, University Hospital Jena, 07740, Jena, Germany. Heidrun.Rhode@med.uni-jena.de.
Petra MuckovaInstitute of Biochemistry I, Nonnenplan 2-4, University Hospital Jena, 07740, Jena, Germany.
Rita BüchlerInstitute of Biochemistry I, Nonnenplan 2-4, University Hospital Jena, 07740, Jena, Germany.
Sindy WendlerInstitute of Biochemistry I, Nonnenplan 2-4, University Hospital Jena, 07740, Jena, Germany.
Bärbel TautkusInstitute of Biochemistry I, Nonnenplan 2-4, University Hospital Jena, 07740, Jena, Germany.
Michaela VogelInstitute of Biochemistry I, Nonnenplan 2-4, University Hospital Jena, 07740, Jena, Germany.
Thomas MooreAnalytik Jena, Konrad-Zuse-Str.1, 07745, Jena, Germany.
Julian GrosskreutzDepartment of Neurology, Am Klinikum 1, University Hospital Jena, 07747, Jena, Germany.
Andree KlemmKfH Kuratorium für Dialyse und Nierentransplantation e.V., Ernst-Ruska-Ring 19, 07745, Jena, Germany.
Mary NabityDepartment of Veterinary Pathobiology, College of Veterinary Medicine, 4467 TAMU, Texas A&M University, College Station, TX, 77843-4467, Texas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteomic biomarker search requires the greatest analytical reproducibility and detailed information on altered proteoforms. Our protein pre-fractionation applies orthogonal native chromatography and conserves important features of protein variants such as native molecular weight, charge and major glycans. Moreover, we maximized reproducibility of sample pre-fractionation and preparation before mass spectrometry by parallelization and automation. In blood plasma and cerebrospinal fluid (CSF), most proteins, including candidate biomarkers, distribute into a multitude of chromatographic clusters. Plasma albumin, for example, divides into 15-17 clusters. As an example of our technique, we analyzed these albumin clusters from healthy volunteers and from dogs and identified cluster-typical modification patterns. Renal disease further modifies these patterns. In human CSF, we found only a subset of proteoforms with fewer modifications than in plasma. We infer from this example that our method can be used to identify and characterize distinct proteoforms and, optionally, enrich them, thereby yielding the characteristics of proteoform-selective biomarkers.

Indexed as

AlbuminsProtein Processing, Post-TranslationalProteomeProteomicsAdultAnimalsChemical FractionationChromatography, GelChromatography, LiquidDogsHumansProtein DenaturationTandem Mass SpectrometryAlbuminsProteome

Identifiers

PMID31409882
PMCPMC6692309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.